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Abstract 
Introduction: Thalassemia Major Illness is mainly created as a progressive hemolytic anemia within the next 
six months of life after birth. Therefore, the aim of the present study is to evaluate the level of growth hormone 
secretion in patients with thalassemia major. Methods: The present research is a descriptive-analytic study. 97 
patients with major thalassemia were selected. All patients test files were examined. Demographic information of 
each patient was gathered using a questionnaire. Fasting blood samples were taken from patients and the level of 
growth hormone was measured. Results: The participants of the study were 95 patients (48 males and 47 females). 
The youngest patient was a seven-month girl and the oldest one was a 27- year- old girl. The average age of 
patients was 13.48 years old. All patients were under transfusion. After stimulation with clonidine, 45.26% and 
54.74% of patients did not have a significant increase in growth hormone and growth hormone secretion, 
respectively. Conclusion: The study indicates that there is a significant relationship between Failure to thrive (FTT) 
and thalassemia patients. And the highest degree of FTT is at the age of over 14 years and poor control of plasma 
ferritin level plays an important role in delayed puberty. Therefore, in order to prevent FTT, patients are required to 
be regularly examined in terms of growth rate and the factors involved in FTT should be determined and 
appropriate preventive measures should be taken. 
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Introduction  
Today, chronic diseases are the major cause of 
health problems in developed countries. Such diseases 
occur in all age groups, social and economic classes, 
and different cultures. It is anticipated that by 2050, 
167 million people will be affected by chronic disease. 
According to information obtained from the United 
States National Research Association, 15 -18 percent of 
children and adolescents suffer from chronic disease, 
which has nearly doubled over the last two decades (1). 
β thalassemia major is one of the chronic diseases that 
threaten the children's health. The World Health 
Organization has identified thalassemia as the most 
commonly diagnosed chronic genetic disorder in 60 
countries, affecting about 100,000 children a year (2). 
Thalassemia is a heterogeneous group of Hereditary 
Hemolytic Anemias which are in common with 
reducing the amount of synthesis of one or more globin 
polypeptides. Due to the type of trapped chain in 
thalassemia patients, the disease can be divided into 
two groups: α-thalassemia and β-thalassemia 
syndromes (3, 4).  There are more than two million beta 
thalassemia carriers and more than 15,000 people live 
with β thalassemia major in Iran (6). The outbreak of 
beta-carriers in Iran, in the Northern provinces of Iran 
(Golestan and Mazandaran provinces) and southern 
coasts (Hormozgan and Khuzestan provinces) is about 
4% (7) , it is more common and is evident more or less 
in other areas. (8). Beta-thalassemia syndromes are 
classified into four subsets in terms of the severity of 
clinical symptoms: silent carriers, β thalassemia minor, 
intermedia thalassemia, and thalassemia major (9, 10). 
Beta-thalassemia major is one of the diseases in which 
normal human development is impaired due to 
complications from the disease (11). The growth 
retardation in beta-thalassemia patients depends on 
several factors that can be attributed to chronic anemia, 
folic acid deficiency, overactive spleen, endocrine 
disruption, zinc deficiency and Desferal poisoning [12]. 
Thalassemia treatment is performed in patients with β 
thalassemia major via bone marrow transplantation and 
blood transfusion (13, 14). Bone marrow transplant is a 
certain cure for thalassemia major (15, 16). The most 
important part of patients' treatment with thalassemia 
major is a blood transfusion, which includes various 
goals (17). Blood transfusions in such patients are based 
on the Thalassemia International Federation (TIF) 
protocol. Blood transfusion treatment in thalassemia 
patients leads to removing hypoxia pressure and severity 
of erythropoiesis and also reduces the absorption of iron 
from the digestive system. On the other hand, it 
increases the iron overload due to blood transfusion in 
these patients (18). Despite clinical benefits of repeated 
blood transfusions in such patients, it can lead to an 
inevitable Hemosiderosis in the long run and cause 
tissue impairment in the form of liver disorders, heart 
failure, growth disorders, hypogonadism, 
hypothyroidism and parathyroidism, and Diabetes (19, 
20). To prevent such complications, extra iron should be 
removed by iron removal (usually done with 
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deferoxamine), while endocrine disorders are still seen 
in these patients, as they get older some of these 
complications increase (21, 22).  Growth disorder is a 
clear phenomenon in patients with thalassemia, which is 
often associated with diminished growth in moderate 
retardation. Delay in growth and short stature is 
observed in more than 40% of thalassemia patients. 
Generally, the decline in the rate of growth begins at the 
age of 10-11 and then continues, so that the height of 
such children is less than the average height of parents 
(7, 15).  Short stature in thalassemia patients has been 
abundant in spite of regular blood transfusions and 
chelator therapy (iron reducing agents). Several factors 
such as abnormal gonadotropin secretion during 
puberty, poor acceptance of iron regimen (iron 
accumulation), inappropriate diet, liver disease, zinc 
deficiency, GH-IGF1 axis disorders and bone dysplasia 
after taking deferoxamine (toxic effect) are effective in 
Short stature (23,24). The cause of growth impairment 
in children is due to the low activity of somatomedin, 
which is a kind of protein that the growth hormone 
induces by its effect. Because the growth hormone was 
induced by cells in vitro, there was no significant 
change in their growth. Since somatomedin is made by 
the liver, Liver hemosiderosis is responsible for 
premature growth impairment (25).  Therefore, due to 
the large number of thalassemia patients and 
considering growth hormone disorders which are the 
most common in thalassemic patients, the aim of the 
present study is to investigate growth hormone 
disorders in thalassemia patients. 
 
Materials and Methods 
The cross-sectional descriptive-analytic study 
was conducted in thalassemia center in Qazvin-Iran. 
The population of the present study included 97 patients 
with β-thalassemia major (previously diagnosed and 
confirmed) covered by Qazvin-Iran thalassemia center 
(located in Quds Hospital). There existed all the 
patients' folder in Quds Thalassemia Center. First, 
demographic information for each patient was gathered, 
then, a fasting blood sample was taken. After, they were 
given clonidine based on their weight, (0.005 mg / kg) 
to stimulate growth hormone (mg / kg). After 120-190 
min (peak growth hormone secretion), the next sample 
was taken to determine the stimulated growth hormone 
level. Then, Samples were transferred to the Quds 
hospital laboratory. After centrifugation and separation 
of the serum from the clot, the samples were transferred 
to the hormone section of the Bu-Ali Sina laboratory in 
Qazvin-Iran. Freeze samples were kept in a lab and 
melted for testing once. Inappropriate, suspected or 
hemolytic samples (2 samples) were excluded in the 
study. Experiments were carried out using Immuno tech 
kit method with high precision. The study is based on 
IRMA (Immuno Radiometric Assay) method which is 
one of the labeled radioisotope methods with high 
accuracy. Then, the results and the information in the 
patients' questionnaire (such as age, sex, time of 
transfusion, number of transfusion per month) and the 
level of ferritin in patients were analyzed. 
 
 
Results 
The following results have been obtained in 95 
patients with β thalassemia major in thalassemia 
department of Quds Hospital. A total of 95 patients with 
beta-thalassemia major were 48 males (52/50%) and 47 
females (48/49%), respectively. 26.5% were at the age 
of under 5 years old, 24.21% at the age of 9-5 years, 
26.31% at the age of 10-14 years, 27.36% at the age of 
19-15 Year, and 16.66% at the age of over 20 years 
(Table 1). The highest number of patients belonged to 
26 persons at the age of 19 -15 years old (27.36%) and 
the lowest number of patients were 5 persons (5. 26%) 
at the age of less than 5 years. 
 
Table 1: Relative Frequency Distribution of patients 
with Thalassemia major According to Age  
 
 
The youngest patient was a 7-month-year-old 
baby girl and the oldest patient was a   27- year- old girl. 
The average age of patients was 13.48 years. The 
average age of onset of blood transfusion was 13 months 
years of age. The earliest onset of blood transfusion was 
from 3 months and the shortest time was 10 years old. A 
total 95 patients, one person once 40 days, 45 people 
once per month, 37 persons twice every month, 11 
persons once 20 days, and one person once 10 days 
received blood. A total of patients, 82.75% consumed 
Desferal irregularly and 17.25% consumed Desferal 
regularly (Table 2). 
 
Table 2: Relative Frequency Distribution of patients 
with Thalassemia Major According to Desferal 
Consumption 
 
 
80 patients have had ferritin measurements in 
which 2 patients (2. 5%) had ferritin below 1000 ng/dl, 
19 persons (23.75%) at the range of 1000-1000 ng/dl,  
28 persons (35%) at the range of 3000-2000 ng/dl ,and 
31persons (38.75% ) greater than 3,000 ng/dl. The 
highest (38.75%) and the lowest (2.5%) number of 
patients with ferritin level were above 3000 ng/dl and 
below 1000 ng/dl, respectively. The lowest amount of 
ferritin was 600 ng/dl and the highest one was 8350 ng/
dl. The following results were obtained in evaluating the 
response rate of the growth hormone secretion to 
clonidine stimulation: 42 patients (45.26%) had an 
increase of more than 5-7 ng/dl in response to 
stimulation with clonidine which indicates an 
appropriate response. 52 patients (54.74%) had a normal 
Age Percent Number 
5> 5.26 5 
5-9 24.21 23 
10-14 26.31 25 
15-19 27.36 26 
20< 16.86 16 
Desferal Consumption Percent 
Regular Consumption 17.25 
Irregular Consumption 82.75 
Total 100 
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increase in response to stimulation with clonidine which 
indicates the growth hormone secretion disorder. Out of 
52 patients with growth hormone disorder, 4 patients 
(7.69%) were at the age of under 5 years old, 14 
(26.99%) were at the age of 5-9 years, 16 (30.76%) 
were at the age of 10-14 years, 13 (25%) were at the age 
of 15-19 years, and 5 patients (9.63%) were at the age of 
over 20 years old.  
 
Table 3: Distribution of patients with growth 
hormone secretion disorder 
 
 
Discussion 
Despite all the advances have been made in the 
treatment of patients with β thalassemia major, FTT is 
still a major problem in these patients (26).  
Thalassemia major illness is a severe form of β 
thalassemia which causes ineffective bone marrow 
activity, hemolytic, and severe and progressive anemia 
and patients usually will be dependent on blood 
transfusions in the first year of life (27). According to 
the various studies conducted in endocrine changes in 
patients with thalassemia major, different hormonal 
disorders have been observed which are due to iron 
overload disposition from transfusion. Growth hormone 
secretion disorders are one of the most common 
endocrine disrupters in such patients (28, 29). In this 
study, 54.74% of the patients with thalassemia major 
had growth hormone secretion disorder and 45.26% of 
the growth hormone secretion was normal. In a study 
conducted at Shahid Beheshti University of Medical 
Sciences in Iran, it has also been reported that there is a 
low level of growth hormone secretion in a number of 
patients with thalassemia major, while some have no 
growth hormone secretion disorder (30). A research 
which was conducted Khalili et al. indicated that more 
than 90% of patients with β-thalassemia major had a 
growth rate of less than 50% (31). In related studies, it is 
reported that short stature was a common complication 
in such patients (32).  Shiva et al. found out more than 
50% of the patients over 10 years of age had short 
stature, and only 10% of the patients under the age of 10 
were short stature (33). Although the growth retardation 
in patients with β-thalassemic began in the first decade, 
it usually drops at the age of 9-10 years old using 
today's treatments and a significant percentage of these 
patients ultimately become short stature (34). In the 
present study, the most common age group of people 
with growth hormone secretion disorder is 10-14 years 
old (puberty). According to the available sources, most 
of the iron overloads including progressive cardiac, liver 
and endocrine is created in the second decade of life. In 
addition, it was observed that the more the serum 
ferritin levels increase, the more the number of patients 
with growth hormone secretion disorder increase (in 
  
  
  
 52 patients 
Age Number (percent) 
<5 4 (7.69%) 
5-9 14 (26.99%) 
10-14 16 (30.76%) 
15-19 13 (25%) 
>20 5 (9.63%) 
particular, levels> 3000 ng/dl). According to the 
available sources, iron overload with high levels of 
ferritin is the main cause of endocrine disorder function 
including pituitary and reduction of growth hormone 
(28). In a study done by Gulati et al (2000) 84 patients 
with thalassemia major were observed in which 51% of 
the patients were with GH deficiency, 10 out of 11 
adults were with hypogonadism, and out of 54 children 
who were under dynamic testing before puberty,18 
patients showed endocrine disorder and short-term 
growth (8). According to the present research and 
previous studies, growth defects in patients with 
thalassemia depend on several factors. One of the most 
important negative factors are the toxic and harmful 
effects of Deferoxamine and Desferal which are mainly 
due to the increased iron levels.  
 
Conclusion 
The results of the present study indicate that 
patients with β-thalassemia major have been at 
increased risk of growth disorders and it increases with 
age.  Therefore, it is necessary to be monitored 
regularly at the beginning of life in terms of growth 
condition, and the factors involved in their 
developmental disorder should be identified in time and 
appropriate preventive measures are required to be 
taken.  
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